File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Termination of pregnancy with reduced doses of mifepristone

TitleTermination of pregnancy with reduced doses of mifepristone
Authors
Issue Date1993
Citation
British Medical Journal, 1993, v. 307 n. 6903, p. 532-537 How to Cite?
AbstractObjectives - To compare the abortifacient efficacy and side effects of three doses of the antiprogestin mifepristone plus prostaglandin for termination of early pregnancy. Design - Randomised, double blind multicentre trial. Setting - 11 departments of obstetrics and gynaecology and of family planning, mostly in university hospitals, in seven countries. Subjects - 1182 women with an early pregnancy (menstrual delay of 7-28 days) requesting abortion. Interventions - Single doses of 200 mg, 400 mg, or 600 mg mifepristone followed, 48 hours later, by vaginal pessary of 1 mg of the prostaglandin E1 analogue gemeprost. Main outcome measures - Outcome of treatment; duration and subjective amount of menstrual bleeding; side effects and complications; and concentration of haemoglobin. Results - Outcome was similar with the three doses of mifepristone. Of the 1151 women with known outcome, 95.5% had a complete abortion (364 (93.8%) of those given 200 mg mifepristone, 368 (94.1%) of those given 400 mg, and 367 (94.3%) of those given 600 mg), 3.7% had an incomplete abortion (14 (3.6%), 15 (3.8%), and 14 (3.6%)), 0.3% had a missed abortion (three (0.8%), one (0.3%), and none), and 0.4% had a continuing live pregnancy (two (0.5%), two (0.5%), and one (0.3%)). Of the 43 women who had incomplete abortion, 23 underwent emergency uterine curettage (usually for haemostatic purposes) and three of these women who had incomplete abortion, 23 underwent emergency uterine curettage (usually for haemostatic purposes) and three of these women were given a blood transfusion. The numbers of reported complaints, bleeding patterns, and changes in blood pressure and haemoglobin concentrations were similar with the three treatments. Conclusions - For termination of early pregnancy a single dose of 200 mg mifepristone is as effective as the currently recommended dose of 600 mg when used in combination with a vaginal pessary of 1 mg gemeprost.
Persistent Identifierhttp://hdl.handle.net/10722/173182
ISSN
2008 Impact Factor: 12.827
2015 SCImago Journal Rankings: 2.567

 

DC FieldValueLanguage
dc.contributor.authorVan Look, PFAen_US
dc.contributor.authorHenshaw, Ren_US
dc.contributor.authorNorman, Jen_US
dc.contributor.authorThong, KJen_US
dc.contributor.authorGomez Alzugaray, Men_US
dc.contributor.authorHo, PCen_US
dc.contributor.authorPretnarDarovec, Aen_US
dc.contributor.authorSajina, Ben_US
dc.contributor.authorPerotti, Len_US
dc.contributor.authorWyssling, Hen_US
dc.contributor.authorChen, JKen_US
dc.contributor.authorZhu, JHen_US
dc.contributor.authorSwahn, MLen_US
dc.contributor.authorKovacs, Len_US
dc.contributor.authorGuocsai, Gen_US
dc.contributor.authorSong, Len_US
dc.contributor.authorWang, YJen_US
dc.contributor.authorBelsey, EMen_US
dc.contributor.authorBernersLee, Nen_US
dc.date.accessioned2012-10-30T06:28:23Z-
dc.date.available2012-10-30T06:28:23Z-
dc.date.issued1993en_US
dc.identifier.citationBritish Medical Journal, 1993, v. 307 n. 6903, p. 532-537en_US
dc.identifier.issn0959-8146en_US
dc.identifier.urihttp://hdl.handle.net/10722/173182-
dc.description.abstractObjectives - To compare the abortifacient efficacy and side effects of three doses of the antiprogestin mifepristone plus prostaglandin for termination of early pregnancy. Design - Randomised, double blind multicentre trial. Setting - 11 departments of obstetrics and gynaecology and of family planning, mostly in university hospitals, in seven countries. Subjects - 1182 women with an early pregnancy (menstrual delay of 7-28 days) requesting abortion. Interventions - Single doses of 200 mg, 400 mg, or 600 mg mifepristone followed, 48 hours later, by vaginal pessary of 1 mg of the prostaglandin E1 analogue gemeprost. Main outcome measures - Outcome of treatment; duration and subjective amount of menstrual bleeding; side effects and complications; and concentration of haemoglobin. Results - Outcome was similar with the three doses of mifepristone. Of the 1151 women with known outcome, 95.5% had a complete abortion (364 (93.8%) of those given 200 mg mifepristone, 368 (94.1%) of those given 400 mg, and 367 (94.3%) of those given 600 mg), 3.7% had an incomplete abortion (14 (3.6%), 15 (3.8%), and 14 (3.6%)), 0.3% had a missed abortion (three (0.8%), one (0.3%), and none), and 0.4% had a continuing live pregnancy (two (0.5%), two (0.5%), and one (0.3%)). Of the 43 women who had incomplete abortion, 23 underwent emergency uterine curettage (usually for haemostatic purposes) and three of these women who had incomplete abortion, 23 underwent emergency uterine curettage (usually for haemostatic purposes) and three of these women were given a blood transfusion. The numbers of reported complaints, bleeding patterns, and changes in blood pressure and haemoglobin concentrations were similar with the three treatments. Conclusions - For termination of early pregnancy a single dose of 200 mg mifepristone is as effective as the currently recommended dose of 600 mg when used in combination with a vaginal pessary of 1 mg gemeprost.en_US
dc.languageengen_US
dc.relation.ispartofBritish Medical Journalen_US
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshAbortion, Induceden_US
dc.subject.meshAdulten_US
dc.subject.meshAlprostadil - Administration & Dosage - Adverse Effects - Analogs & Derivativesen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosage - Adverse Effectsen_US
dc.subject.meshPessariesen_US
dc.subject.meshPregnancyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleTermination of pregnancy with reduced doses of mifepristoneen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8400972-
dc.identifier.scopuseid_2-s2.0-0027185396en_US
dc.identifier.volume307en_US
dc.identifier.issue6903en_US
dc.identifier.spage532en_US
dc.identifier.epage537en_US
dc.identifier.scopusauthoridVan Look, PFA=7005176694en_US
dc.identifier.scopusauthoridHenshaw, R=7004042821en_US
dc.identifier.scopusauthoridNorman, J=7402489769en_US
dc.identifier.scopusauthoridThong, KJ=7005739732en_US
dc.identifier.scopusauthoridGomez Alzugaray, M=6506187382en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridPretnarDarovec, A=6602910640en_US
dc.identifier.scopusauthoridSajina, B=6504441327en_US
dc.identifier.scopusauthoridPerotti, L=6701399933en_US
dc.identifier.scopusauthoridWyssling, H=6602258079en_US
dc.identifier.scopusauthoridChen, JK=7501889344en_US
dc.identifier.scopusauthoridZhu, JH=7405687976en_US
dc.identifier.scopusauthoridSwahn, ML=7003475672en_US
dc.identifier.scopusauthoridKovacs, L=24348044800en_US
dc.identifier.scopusauthoridGuocsai, G=6504279036en_US
dc.identifier.scopusauthoridSong, L=7402538048en_US
dc.identifier.scopusauthoridWang, YJ=7601494191en_US
dc.identifier.scopusauthoridBelsey, EM=35885076200en_US
dc.identifier.scopusauthoridBernersLee, N=6507862311en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats